Goldman Sachs analyst James Quigley maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...

Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report) and keeping the price ...

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...

Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that will be closely compared with a rival product from Eli Lilly. Novartis ...

Today, the Lonza Board of Directors announced the nomination of Juan Andres and Eric Drapé as Independent Members of the Board. The Board will propose to shareholders the election of both nominees at ...

The FDA yesterday approved Novartis’ Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers, significantly expanding the number of patients who will ...

A judge in the US has denied an attempt by Novartis to stop MSN Pharmaceuticals from launching a generic version of heart failure blockbuster Entresto. MSN Pharma was given FDA approval for its ...

Siemens Healthineers has agreed a €200 million ($224 million) deal to buy the diagnostic arm of Novartis' Advanced Accelerator Applications (AAA) radiopharma unit, boosting its medical imaging ...

Palisade Bio is fortifying its brand image. The California-based biotech on Monday unveiled a new logo and website design, ...

“Novartis is committed to understanding and solving some of the most burdensome neurological conditions to improve the quality of life for patients and their caregivers, and to make a positive impact ...

After hours: September 20 at 7:39 PM EDT Loading Chart for NVS ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.